β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing
earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated
in this combined extension 3 study for any new gouty arthritis flare on demand with one
subcutaneous (s.c.) injection of canakinumab 150 mg.